Plan is a pre-market intraday long in NVO based on a clear, fresh FDA catalyst and strengthening short-term momentum. 1) Catalyst & news - Seeking Alpha reports that Novo Nordisk is rising after the FDA approved a Wegovy pill for obesity ("Wegovy Without The Needle Sparks Novo Surge"). That is a major, high-visibility regulatory win, directly tied to the weight‑loss theme that has repeatedly driven multi‑percent moves in NVO and peers. - Social ranking has jumped from 62 to 5 with an "up" trend, confirming new retail attention rather than stale chatter. - Additional coverage pieces frame NVO among strong biotech/health themes for 2025–2026, adding medium‑term positive sentiment even if less relevant intraday. 2) Price action & momentum - Current price: 52.35 vs previous close 48.10, already a sizable move tied to the FDA news, confirming that the tape respects the catalyst. - Short-term trend is turning up: MACD histogram is slightly positive (0.12) and flagged as bullish momentum, while price has reclaimed above the 10‑day SMA (48.68) and the 9‑day EMA (48.36). That suggests the pullback phase off the recent lows (43.08 52‑week low) is shifting toward a recovery leg. - RSI around 47 indicates the stock is not technically overbought yet despite today’s gap, leaving room for continuation. 3) Upside/ downside math (meets ≥4–5% requirement) - Proposed entry: 51.90–52.40. This brackets the current quote (52.35) with room for a small opening dip without chasing an extreme spike. - Target/exit: 54.20–55.00. * From entry floor 51.90 to exit floor 54.20 is +2.30, or 2.30 / 51.90 ≈ 4.4% upside. * From mid-range entry (~52.15) to mid exit (~54.60) is about +4.7%. * Best case to 55 is roughly +6% from 51.90. - Stop loss: 50.70, about 1.20 below entry floor, or ~2.3% downside from 51.90. That yields a favorable reward:risk of roughly 1.9:1 using the 54.20 target. - ATR(14) is ~1.31, so a 2.3–2.6 point upside (vs entry) is only about 1.8–2.0× ATR, a realistic intraday range for a mega‑cap with a fresh FDA approval and heavy volume (16.6M vs 14.4M avg20 already). 4) Additional supporting factors - Short interest is modest (days to cover ~1.2) but rising, and short‑volume ratio is in the high‑30s and ticking up. This doesn’t imply a classic squeeze, but adds incremental buying pressure if shorts trim on the news. - The stock is down ~55% over 1Y and ~32% over 6M, so the FDA pill approval can be framed as a fundamental relief/turning‑point rather than euphoria at all‑time highs. - Liquidity is excellent (market cap >$230B, daily volume >10M), making it suitable for intraday entries/exits. 5) Intraday execution notes - Bias: Long only. Avoid chasing if it spikes above 53+ immediately on the open; better to wait for a controlled pullback into the 51.9–52.4 zone with stabilization on 1–5 minute candles. - Time horizon: 3–6 hours. Look for the move to develop by late morning to early afternoon; if NVO stalls under 53 on weak volume for most of the session, consider tightening stops or taking partials earlier. - Invalidations: A decisive break and hold below 51.0 (well under the stop) or a sharp, high‑volume reversal on clear negative follow‑up commentary about the pill’s label, safety, or reimbursement would negate the setup. Given the strong FDA catalyst, improving technicals off depressed levels, and a clearly defined 4–6% intraday upside versus ~2–2.5% risk, this setup supports a long day trade in NVO with ~80% confidence, provided the open does not extend too far beyond the planned entry band.